Navarro-Navarro M, Moreno-Noriega BO, López-Munguía BE, Fragoso-Carmelo MC, Sánchez-Padilla JA

Language: Spanish
References: 33
Page: 64-70
PDF size: 85.16 Kb.

ABSTRACT

Objective: To know the prevalence of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Design: A prospective, observational, descriptive study, from October 2002 throug April 2003.
Material and Methods. A total of 120 consecutive isolates from clinical samples were identificated. The susceptibility of the isolates to twelve antimicrobial agents was determinated by the Kirby-Bauer disk-diffusion technique according to the NCCLS recommendations. To detect ESBLproduction, we used the double-disk approximation test described by Jarlier et. al. and the doubledisk sinergy test using both cefotaxime and ceftaxidime alone and in combination with clavulanic acid.
Results: The prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae was 5%. The isolates showed co-resistance to non-beta-lactam antimicrobials, especially to trimetoprim/ sulfamethoxazole and amikacin.
Conclusion: Greater procentages of ESBL-production have been reported in México. The present study was the first to assess the prevalence and susceptibility patterns of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Hospital Infantil del Estado de Sonora.

REFERENCES

1. Madeiros AA. Evolution and dissemination of b-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 1997; 24(Suppl. 1): S19-S45.

2. Coudron PE, Moland ES, Sanders CC. Occurrence and detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. J Clin Microbiol 1997; 35: 2593-7.

3. Lucet JC, Decré D, Fichelle A, et. al. Control of a prolonged outbreak of extended-spectrum β-lactamase-producing Enterobacteriaceae in a University Hospital. Clin Infect Dis 1999; 29: 1411-8.

4. Burguess DS, Hall RG, Lewis II JS, Jorgensen JH, Patterson JE. Clinical and microbiologic analysis of a Hospital’s extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy 2003; 23: 1232-7.

5. Pujol M, Peña C. El significado clínico de las betalactamasas de espectro extendido. Enferm Infecc Microbiol Clin 2003; 21:69-71.

6. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.

7. Emery CL, Weymouth LA. Detection and clinical significance of extended-spectrum β-lactamases in a tertiary-care medical center. J Clin Microbiol 1997; 35: 2061-7.

8. Rice L. Evolution and clinical importance of extended-spectrum β-lactamases. Chest 2001; 119: 391S-396S.

9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. NCCLS Approved Standard M100-S10. National Committee for Clinical Laboratory Standards, ed. Wayne, PA, 2000.

10. Paterson DL, Yu VL. Editorial response: Extended-spectrum β-lactamases: a call for improved detection and control. Clin Infect Dis 1999. 29: 1419-22.

11. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Approved standard for antimicrobial disk susceptibility test. Approved Standard M2-SG-National Committee for Clinical Laboratory Standards, ed. Wayne, PA, 1997.

12. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 8th informational supplement. NCCLS document M100S8. Wayne, PA: National Committee for Clinical Laboratory Standards, 1998.

13. Jarlier V, Nicolas MH, Fournier G, y col. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-78.

14. Livermore DM, Brown DFJ. Detection of β-lactamase-mediated resistanse. J Antimicrob Chemother 2001; 48(Supl S1): 59-64.

15. Alpuche-Aranda CM. Infecciones por Klebsiella pneumoniae, perfil de susceptibilidad y resistencia. Acta Ped Méx 2004; 25: 142-5.

16. Alpuche-Aranda CM, Daza-Timana CA. Infecciones nosocomiales por bacterias Gram negativas resistentes a cefalosporinas de espectro extendido: asociación de dos peligrosos enemigos. Enf Infec y Micro 2002; 22: 192-9.

17. Martínez P, Mercado M, Salim M. Determinación de β-lactamasas de espectro extendido en gérmenes nosocomiales del Hospital San Jerónimo, Montería. Colomb Med 2003; 34: 196-205.

18. Amyes SGB, Miles RS. Extended-spectrum β-lactamases: the role of inhibitors in therapy. J Antimicrobial Chemother 1998; 42: 415-7.

19. Quale JM, Landman D, Bradford PA, y col. Molecular epidemiology of a citywide outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection. Clin Inf Dis 35; 834-41.

20. Mirelis B, Navarro F, Miró E, y col. Community transmisión of extended-spectrum β-lactamase. Emerg Inf Dis 2003; 9: 1024-5.

21. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the western pacific region. Clin Inf Dis 2001; 32(Suppl 2): S94-S103.

22. Rice L. Evolution and clinical importance of extended-spectrum β-lactamases. Chest 2001; 119: 391S-396S.

23. Nordmann P. Trends in β-lactam resistance among enterobacteriaceae. Clin Inf Dis 1998; 27(Suppl 1): S100-S106.

24. Swenson JM, Hindler JA, Peterson LR. Special phenotypic methods for detecting antibacterial resistance, p. 1563-1577. In: Manual of Clinical Microbiology, Murray PR, Jo Baron E, Pfaller MA, Tenover FC, Yolken RH (Ed.). 1999, 7th ed. American Society for Microbiology, WashingtonDC.

25. Quintialini R, Sahm DF, Courvalin P. Mechanisms of resistance to antimicrobial agents, p. 1505-1525. In: Manual of Clinical Microbiology, Murray PR, Jo Baron E, Pfaller MA, Tenover FC, Yolken RH (Ed.). 1999, 7th ed. American Society for Microbiology, Washington DC.

26. Fortineau N, Naas T, Gaillot O, Nordmann P. SHV-type extended-spectrum beta-lactamase in a Shigella flexneri clinical isolate. J Antimicrobial Chemother 2001; 47: 685-8.

27. Nathisuwan S, Burgess DS, Lewis JS. Extended-spectrum β-lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001; 21: 920-8.

28. Samaha-Kfoury JN, Araj GF. Recents developments in β-lactamases and extended-spectrum β-lactamases. BMJ 2003; 327: 1209-13.

29. Chlebiki MP, Oh HML. Extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella spp. In a Singapore Hospital: clinical spectrum. Ann Acad Med Singapore 2004; 33: 302-6.

30. Gaillot O, Maruéjouls C, Abachin E, y col. Nosocomial oubreak of Klebsiella pneumoniae producing SHV-5 extended-spectrum β-lactamase, originating from a contaminated ultrasonography coupling gel. J Clin Microbiol 1998; 36: 1357-60.

31. Daoud Z, Hakime N. Prevalence and susceptibility patterns of extended-spectrum betalactamase- producing Escherichia coli and Klebsiella pneumoniae in a General University Hospital in Beirut, Lebanon. Rev Esp Quimiot 2003; 16: 233-8.

32. Dancer SJ. The problem with cephalosporins. J Antimicrobial Chemother 2001; 48: 463-78.

33. Burguess DS, Hall RG, Lewis II JS y col. Clinical and microbiological analysis of a Hospital’s extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy 2003; 23: 1232-7.